Showing 2311-2320 of 5771 results for "".
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cellshttps://modernod.com/news/noveome-biotherapeutics-announces-publication-of-further-preclinical-results-supporting-the-neuroprotective-properties-of-st266-in-retinal-ganglion-cells/2476572/Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with e
- GenSight Biologics Announces Positive Data for PIONEER Phase 1/2 Clinical Trial of GS030 for the Treatment of RPhttps://modernod.com/news/gensight-biologics-announces-positive-data-for-pioneer-phase-1-2-clinical-trial-of-gs030-for-the-treatment-of-rp/2476561/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its first safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, combining gene therapy and optogenetics for the treatment of retinitis pigmentosa. The DSMB confirmed the absence of an
- Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRShttps://modernod.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/Eyenovia announced the safety and efficacy results from the company’s two phase 3 trials, MIST-1 and MIST-2, for pharmacologic mydriasis (pupil dilation). The results were presented by David Wirta, MD, from the podium during the joint ASCRS-ASOA annual meeting, on May 5, 2019 in S
- Zeiss Announces New Breakthroughs in Digital Technology and High-Resolution Imaging at ASCRShttps://modernod.com/news/zeiss-announces-new-breakthroughs-in-digital-technology-and-high-resolution-imaging-at-ascrs/2476551/Zeiss Medical Technology Segment will announce several breakthroughs in digital technologies and high-resolution imaging at the American Society of Cataract and Refractive Su
- Sydnexis Announces Enrollment of First Patients in Phase 3 Myopia STAAR Study of SYD-101 in Childrenhttps://modernod.com/news/sydnexis-announces-enrollment-of-first-patients-in-phase-3-myopia-staar-study-of-syd-101-in-children/2476532/Sydnexis announced that the first patients have been successfully dosed in a phase 3 multicenter trial of SYD-101, following FDA clearance of Sydnexis’ IND in April. Sydnexis’ STAAR study will be
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Staar Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL in Germany and Japanhttps://modernod.com/news/staar-surgical-announces-expanded-recommended-diopter-range-for-evo-visian-icl-in-germany-and-japan/2476531/Staar Surgical announced that leading refractive ophthalmic societies in Germany and Japan have increased the diopter range for recommended use of phakic refractive lenses, including the EVO Visian ICL, to -3.0 diopters from -6.0 diopters. The German society, the Kommission Refraktive Chir
- Sight Sciences Announces Launches of TearCare and the Enhanced OMNI Systemhttps://modernod.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/Sight Sciences announced the official commercial launch of TearCare and the introduction of an aesthetically and ergonomically enhanced OMNI Surgical System, which was initially launched in February 2018. The rollout of the new devices will include product dem